Relation between carotid intima media thickness and oxidative stress markers in type 1 diabetic children and adolescents by Mona H El Samahy et al.
El Samahy et al. Journal of Diabetes & Metabolic Disorders 2013, 12:50
http://www.jdmdonline.com/content/12/1/50RESEARCH ARTICLE Open AccessRelation between carotid intima media thickness
and oxidative stress markers in type 1 diabetic
children and adolescents
Mona H El Samahy1, Randa M Matter1, Omneya I Youssef1*, Manal A Shams El Din El Telbany2 and Nermeen A Kamal1Abstract
Background: Carotid intima media thickness (CIMT) is a non invasive marker of subclinical atherosclerosis.
Hyperglycemia, oxidatively modified atherogenic lipoproteins and advanced glycation end products are linked to
increased oxidative stress in diabetes. We aimed to find out the relation between carotid intima media thickness in
type 1 diabetic children and adolescents and plasma nitric oxide and total antioxidant capacity levels as markers of
oxidative stress.
Methods: This study included 50 children and adolescents with type 1 diabetes mellitus with mean age
(9.7 ± 3.4 years) and 50 healthy age and sex matched controls. They were subjected to assessment of hemoglobin
A1c, total cholesterol and triglycerides, serum total antioxidant capacity, serum nitric oxide (NO) by colorimetric
method and carotid intima media thickness by B-mode ultrasound.
Results: There was significant elevation in serum nitric oxide (17.07 ± 6.4 vs 12.6 ± 4.7 μmol/L; p < 0.001), CIMT
(0.47 ± 0.04 vs 0.39 ± 0.02 mm; p < 0.001) and significant reduction in serum total antioxidant capacity (0.41 ± 0.29
vs 0.87 ± 0.23 mmol/L; p < 0.001) in diabetic patients compared to controls. Carotid intima media thickness was
correlated positively with nitric oxide (r = 0.402, p = 0.01) and negatively with total antioxidant capacity (r = −0.341,
p = 0.02). Carotid intima media thickness was also correlated positively with age, duration of diabetes but not
correlated with glycemic control or lipid profile.
Conclusion: The significant elevation in nitric oxide and reduction in total antioxidant capacity in children and
adolescents with type 1 diabetes mellitus with their correlation with carotid intima media thickness may reflect
the role of oxidative stress in the development of atherosclerosis in young type 1 diabetic subjects.Introduction
The atherogenicity of type 1 diabetes has been increas-
ingly recognized [1]. Patients with diabetes show a 2- to
10-fold risk for developing atherosclerotic lesions com-
pared with the normal population [2,3]. Even if these
complications become manifest in the adult diabetic
patient, the process of vascular changes starts much
earlier [4,5]. The most significant changes in early sub-
clinical period of atherosclerotic disease are endothelial
dysfunction and increase in intima-media thickness
observed in all arterial beds [6]. Common carotid artery
intima-media thickness (CIMT), measured by high-* Correspondence: ibrahim_omneya@yahoo.com
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reproduction in any medium, provided the orresolution B-mode ultrasonography, is a noninvasive
marker of subclinical atherosclerosis [7-9]. Normative
values for CIMT are available for subjects aged 10 to
20 years [10,11].
Mechanisms involved in the increased oxidative stress
in diabetes include not only oxygen free radical generation
due to nonenzymatic glycosylation (glycation), autooxida-
tion of glycation products, but also changes in the tissue
content and activity of antioxidant defense systems.
Increased levels of the products of oxidative damage to
lipids have been detected in serum of diabetic patients,
and their presence correlates with the development of
complications [12-18].
Oxidative stress plays a pivotal role in the deve-
lopment of diabetes microvascular and cardiovascular
complications [19].tral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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appears to be a consequence of increased oxidation of
fatty acids, resulting in part from pathway-specific insu-
lin resistance [19].
Nitric oxide has cellular antioxidant and pro-oxidant ac-
tions [20]. The endothelial nitric oxide (NO) system plays
a pivotal role in vascular physiology and pathology. NO is
a potent vasodilator agent with anti-hypertensive, anti-
thrombotic, anti-atherogenic, and anti-smooth muscle
proliferative properties [21]. However, high amounts of
NO produced by inducible NO synthase (iNOS) and/or
peroxynitrite (ONOO−), a reactive intermediate of NO
with superoxide anion are involved in pro-inflammatory
reactions and tissue damage as well [22].
Total Antioxidant Capacity (TAC) is capable of serving
as a parameter to monitor diabetes in patients with type
1 DM [23]. A depletion of the total antioxidant capacity
is associated with a higher incidence of diabetic compli-
cations [24].
The relation between oxidative stress markers and
carotid intima media thickness in type 1 diabetic children
and adolescents was not extensively studied. Hence, this
study aimed at assessment of carotid intima media
thickness in children and adolescents with type1 diabetes
mellitus in relation to plasma nitric oxide and plasma total
antioxidant capacity levels and with diabetes duration,
glycemic control and microvascular complications.Patients and methods
This case control study was conducted at the Pediatric
Diabetes Clinic, Children’s Hospital, Ain Shams University,
Cairo, Egypt in the period from April 2011 to February
2012.It included 50 patients with type 1 diabetes mellitus
(DM) regularly attending the clinic. They were 37 females
(74%) and 13 males (36%). Their ages ranged from 6–
16 years with a mean age of 9.7 ± 3.4 years. Their duration
of illness ranged from 1–13 years with mean diabetes dur-
ation of 4.5 ± 3.5 years. Patients were further subdivided
into two groups according to the duration of diabetes:
(Group I) included 22 children and adolescents with
diabetes duration of 5 years or more, (Group II) included
28 children and adolescents with diabetes duration of less
than 5 years. Fifty age and sex matched healthy individuals
were included as a control group. They were 14 males and
36 females. Their age ranged from 2–14 years with mean
age of 9.8 ± 3.14 years.
The study was approved by the Ethical Committee of
Ain Shams University Faculty of Medicine.Inclusion criteria
Patients were included in the study only if they have
type 1 diabetes mellitus on regular insulin therapy
regularly visiting the Clinic.Exclusion criteria
Included Type 2 diabetes mellitus, hypertension, patients
with malignancy, connective tissue diseases, liver dysfunc-
tion, renal dysfunction (serum creatinine > 1.2 mg/dl),
congenital or acquired cardiovascular disorders, adminis-
tration of drugs other than insulin (such as oral hypogly-
cemics, antihypertensives, antiplatelets or lipid lowering
medications, aspirin, or vitamin supplements) at the time
of the study and none of them was cigarette smoker.
All patients were subjected to detailed history
taking, thorough clinical examination, measurement of
Glycosylated Hb (HbA1c) by HPLC (high performance
liquid Chromatography). Patients were considered under
optimal glycemic control when their HbA1c was < 7.5%
[25]. Microalbuminuria was assayed using SERA-PAK
immuno-microalbumin Kit (Bayer Corporation, Benedict
Ave, Tarry town, NY, USA). Persistent microalbuminuria
was defined when two of three samples showed urinary
albumin excretion rate of 30–300 μg/mg creatinine
[26] fasting serum triglycerides, serum cholesterol
using Synchron CX7 (Brea, California, USA) [27]. Serum
total antioxidant capacity by colorimetric method [28],
serum NO by colorimetric method [29] and Carotid
intimal –media thickness (CIMT) assessment using B
mode ultrasonography [30].
Measurment of serum Total Antioxidant Capacity
(TAC) by colorimetric method.
The determination of antioxidative capacity was per-
formed by the reaction of antioxidants in the sample
with a defined amount of exogenously provide hydrogen
peroxide (H2O2) the antioxidants in the sample elimin-
ate a certain amount of the provided hydrogen peroxide.
The residual H2O2 was determined clorometrically by
an enzymatic reaction which Involves the conversion of
3,5,dichloro _2_ hydroxyl benzensulphonate to a colored
product [28].
Measurement of serum Nitric oxide (NO) was done
using colorimetric method. This assay determines nitric
oxide concentrations based on the enzymatic conversion
of nitrate to nitrite by nitrate reductase. The reaction is
followed by colorimetric detection of nitrite as an azo
dye product of the Griess Reaction. The Griess Reaction
is based on the two-step diazotization reaction in which
acidified NO2- produces a nitrosating agent, which
reacts with sulfanilic acid to produce the diazonium ion.
This ion is then coupled to N-(1-naphthyl) ethylenedi-
amine to form the chromophoric azo-dervative which
absorbs light at 540–570 nm [29].
Statistical analysis
Demographic and clinical data are presented as means ±
SD or proportions. Differences in continuous variables
between males and females were tested with the Student
t test for normally distributed data and the Mann–Whitney
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contingency tables with different degrees of freedom
was obtained to detect associations between categorical
independent variables. Adjustment for multiple con-
founding was done using linear regression analysis with
a manual backward procedure. Multivariate analyses
were preceded by estimation of the correlation between
potential confounders. A significance level of < 0.05 was
used. All statistical analysis was done using the SPSS
software package for Windows, version 15.0 (SPSS,
Chicago, IL).
Results
– Patients mean systolic blood pressure (SBP)
was103.500 ± 18.077 mmHg and mean diastolic
blood pressure (DBP) was 68 ± 10.302 mmHg.
Three (6%) of our patients had SBP and
DBP > 95% percentile while 97% were
within the normal ranges.
– Diabetic patients showed significant increase in
nitric oxide and decrease in total antioxidant
capacity level than controls (P value < 0.001)]
(Table 1), Figure 1.
– NO level was higher in patients with
suboptimal glycemic control than those with
optimal glycemic control [(23.38 ± 6.7 μmol/L)
vs (16.33 ± 5.6 μmol/L)] (P value = 0.017) and in
patients with nephropathy than patients
without nephropathy [(22.00 ± 4.14 μmol/L) vs
(16.67 ± 6.5 μmol/L)] (P value = 0.033).
– No statistically significant difference was found in
TAC level between diabetic patients with and
without nephropathy or between patients with
suboptimal and optimal glycemic control
(p value >0.05)Table 1 Comparison between diabetic patients and







Age (years) 9.78 ± 3.45 9.86 ± 3.14 −0.12 0.90
BMI(kg/m2) 20.120 ± 4.155 18.740 ± 3.87 t = 1.72 0.09
Cholesterol (mg/dl) 147.35 ± 38.92 120.68 ± 35.26 t = 3.5 0.0005*
Triglycerides (mg/dl) 80.86 ± 25.10 62.40 ± 20.50 t = 4.03 0.0001*
NO (μmol/L) 17.07 ± 6.36 12.57 ± 4.74 3.98 <0.001*
TAC (mmol/L) 0.41 ± 0.29 0.87 ± 0.23 −8.87 <0.001*
CIMT (mm) 0.47 ± 0.04 0.40 ± 0.02 9.66 <0.001*
Gender 37/13 36/14 0.437# 0.509
NO nitric oxide, TAC Total antioxidant capacity, CIMT carotid intima media
thickness; #= Chi-Square.
*Indicate statistical significance.
Figure 1 Comparison between patients and controls regarding
values of nitric oxide and total antioxidant capacity.– Serum total cholesterol and triglycerides
were significantly higher in studied patients
than control group, although within
normal range.
– Carotid intima media thickness was significantly
increased in diabetic patients compared to normal
Table 2 Comparison between patients with diabetes duration <5 years and >5 years regarding studied parameters
Patients with diabetes duration ≤ 5 years(n = 28) Patients with diabetes duration > 5 years(n = 22) T-test
Mean ± SD Mean ± SD t P-value
Age (years) 7.64 ± 2.80 12.50 ± 1.946 −6.92 <0.001*
Mean HbA1c% 8.47 ± 1.98 9.73 ± 2.07 −2.19 0.03*
Cholesterol (mg/dl) 134.36 ± 38.34 162.50 ± 35.23 −1.94 0.07
Triglycerides (mg/dl) 79.13 ± 24.74 81.86 ± 25.54 0.38 0.7
NO (μmol/L) 16.27 ± 6.70 18.09 ± 5.89 −1.01 0.32
TAC (mmol/L) 0.45 ± 0.31 0.36 ± 0.25 1.18 0.25
CIMT (mm) 0.44 ± 0.03 0.50 ± 0.03 −7.09 <0.001*
NO nitric oxide, TAC Total antioxidant capacity, CIMT carotid intima media thickness.
*Indicate statistical significance.
Table 3 Correlation between CIMT, serum NO and serum
TAC in diabetic patients
CIMT (mm) NO (μmol/L)
Age (years) r 0.741
P-value <0.001*
Duration of diabetes (years) r 0.656
P-value <0.001*
SBP (mmHg) r 0.126
P-value 0.002*
DBP (mmHg) r 0.379
P-value 0.007*
NO (μmol/L) r 0.40
P-value 0.01*
TAC(mmol/L) r −0.34 −0.53
P-value 0.02* <0.001*
CIMT carotid intima media thickness, SBP systolic blood pressure, DBP diastolic
blood pressure, NO nitric oxide, TAC Total antioxidant capacity.
*Indicate statistical significance.
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0.39 ±0.02 mm)] (P < 0.001) (Table 1), Figure 1.
– Carotid intima media thickness was significantly
increased in diabetic patients with suboptimal than
those with optimal glycemic control [(0.46 ± 0.04 cm)
vs (0.40 ± 0.02 cm)] (P value 0.04), in patients with
diabetes duration > 5 years than those with
diabetes duration < 5 years [(0.50 ± 0.03 mm)
vs (0.43 ± 0.02 mm)] (P value <0.001)] (Table 2) and
in diabetic patients with than patients without
nephropathy [ (0.49 ± 0.02) vs (0.40 ± 0.04)]
(P value = 0.009).
– A statistically significant positive correlation was
found between carotid intima media thickness and
age, duration of diabetes mellitus, systolic and
diastolic blood pressure and nitric oxide
(P value < 0.001 and <0.001, 0.002, 0.007 and 0.01
respectively) and a significant negative correlation
was found between carotid intima media thickness
and total antioxidant capacity (P value = 0.02)
(Table 3). No significant correlation was found
between carotid intima media thickness and mean
HbA1c, cholesterol or triglycerides (P value >0.05).
Discussion
The present study showed a significant increase in
serum nitric oxide (NO) level in diabetic patients than
controls which came in agreement with many studies
[31-33]. Pitocco et al. [34] suggested a reduced asym-
metric dimethyl arginine (ADMA) inhibition of NOS as
possible mechanism involved in the pathogenesis of
oxidative stress in female subjects with a short duration
and uncomplicated type 1 diabetes.
Serum NO level was significantly increased in dia-
betic patients with than those without nephropathy
which came in accordance to previous studies [35,36].
Prabhakar, [37] reported that the enhanced NO pro-
duction may contribute to hyperfiltration and microal-
buminuia at early diabetic nephropathy. NO level was
significantly higher in patients with suboptimal thanoptimal glycemic control which came in agreement with
others [38].
A significant decrease in total antioxidant capacity
level was found in patients than controls which came in
agreement with several studies [39-42]. Lack of differ-
ence in TAC level between our studied patients with and
without nephropathy is concordant with El-desoky et al.
[43] who found that plasma TAC in patients of diabetes
mellitus type I with nephropathy was not significantly
decreased as compared with diabetes mellitus type 1
with no nephropathy and they concluded that TAC
cannot be used to differentiate between diabetes mellitus
type 1 with and without nephropathy.
Serum total cholesterol and triglycerides were sig-
nificantly higher in studied diabetic patients compared
to control group although within the normal range. This
agreed with Margeisdottir et al. [44] who attributed
those findings to the young age of the patients.
Diabetic patients showed a significant increase in
CIMT mean values compared to controls. Those results
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cant increase in CIMT in patients with nephropathy
compared to patients without nephropathy came in
concordance with Gul et al. [47] suggesting that diabetic
microangiopathy is related with macroangiopathy and in
patients with suboptimal glycemic control compared to
patients with optimal glycemic control which came in
concordance with Abdelghaffar et al. [46].
CIMT was directly correlated with age in studied
diabetic patients which agreed with many studies [46-48].
A strong direct correlation was found between mean
CIMT and patients systolic and diastolic blood pressure
which agreed with several studies [46,48,49]. The rela-
tionship between increased CIMT and blood pressure
suggests that smooth muscle proliferation plays a
role in the early diffuse thickening of the arterial
wall [49].
No significant correlation was found between mean
CIMT and metabolic control parameter HbA1c, this
agreed with many studies [47,50]. Data from the litera-
ture indicated that, in contrast to the functional impair-
ment of the endothelium, structural changes are not
correlated to single parameter such as the HbA1c at a
young age [50].
A statistically significant positive correlation was found
between carotid intima media thickness and nitric oxide
level which agreed with Dursun et al. [51] who explored
the relation between CIMT and oxidative stress markers
in type 2 diabetic patients on maintenance hemodialysis.
Zineh et al. [52] reported the association between NOS3
polymorphisms and arterial stiffness in children with
type 1 diabetes. Insulin acts by modulating the release of
vasodilator substances, such as nitric oxide and prosta-
glandins, from vascular endothelium, by both stimulating
and inhibiting the sympathetic nervous system and by
protecting smooth muscle cells in blood vessel from apop-
tosis induced by oxidative stress [53]. Thus the vasodila-
tory and antioxidant effects of insulin are depressed in
case of insulin deficiency (i.e. type 1 diabetes) [54].
A negative correlation was found between CIMT and
total antioxidant capacity level. Lower serum TAC levels
were observed in atherosclerotic coronary artery disease
patients with an inverse association with number of
damaged coronary vessels [55]. Other research reported
increased DNA damage in the nucleus of coronary cells
and decreased plasma TAC level in coronary artery
disease patients [56].
Conclusion
The significant elevation in nitric oxide and reduction in
total antioxidant capacity in children and adolescents
with type 1 diabetes mellitus together with their correl-
ation with carotid intima media thickness may reflect
the role of oxidative stress in the development ofatherosclerosis in young type 1 diabetic subject. Further
studies to measure other antioxidant markers like gluta-
thione or antioxidants or markers of oxidative stress like
malondialdehyde in relation to carotid intima media
thickness are warranted.
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